New Milton, UK, 21 May 2009 – Genetix Group plc (AIM:GTX), the cell imaging and analysis group will hold its Annual General Meeting (AGM) today at 11.30 a.m.
During the course of the meeting Charles de Rohan, Chief Executive of Genetix, will make the following statement to shareholders:
“Genetix has made a positive start to the year and is trading in line with our expectations.
While no company is immune from the effects of the global economic conditions, our tightly managed business coupled with our products delivering tangible benefits to our customers, is proving resilient in meeting these challenges.
The successful rebalancing of our product portfolio over the last few years means the Group is in a strong position to capitalise on the growth within its chosen markets of biopharmaceutical drug discovery and diagnostics – markets which allow us to play to our strengths in imaging and intelligent analysis.
We are excited about the opportunities that our recent acquisition of SlidePath present, allowing us to accelerate and strengthen our presence in the growing digital pathology market. Combining SlidePath’s cutting edge products and technologies with our sales and customer support infrastructure in Europe, the United States and Japan, along with our strong customer relationships with diagnostics and pharmaceutical companies will enhance our position in this exciting market.”
About Genetix Group plc
Headquartered in New Milton, UK, with offices in the UK, US, Germany, Ireland and Japan, and quoted on the AIM (GTX: AIM), Genetix provides scientists and clinicians with unrivalled solutions for imaging and intelligent image analysis in the life science and diagnostic markets.
In life sciences, the company’s systems set industry standards for accurate selection of microbial colonies, and for screening and selection of mammalian secretory cell lines. Other systems evaluate the response of cells to potential therapeutic agents and quantify tissue biomarkers.
In diagnostics, Genetix holds a leading position in genetic testing with thousands of the company’s platforms used in laboratories worldwide.
Through its expertise in robotics, cell and molecular biology, image analysis and interpretation, supported by a strong IP portfolio, Genetix is committed to the continual development of innovative solutions.
